USD10
Actions JBIO
À propos de Jade BiosciencesJade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
USD10
Actions JBIO
À propos de Jade BiosciencesJade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Statistiques
FENÊTRE DE TRADING
Fermé
OUVRE À
2 avr. at 13:30 UTC+0
Capitalisation boursière
810,85 M $US
PRIX D'OUVERTURE
Données insuffisantes
BAS (1 an)
2,45 $US
ÉLEVÉ (1 an)
17,71 $US
BAS (24 h)
13,93 $US
ÉLEVÉ (24 h)
16,44 $US
Volume (24 h)
1,64 M $US
209,48 %
Historique des prix
Time | Price | Change |
|---|---|---|
Aujourd'hui | Données insuffisantes | Données insuffisantes |
1 jour | 14,11 $US | |
1 semaine | 13,86 $US | |
1 mois | 14,32 $US | |
1 an | 2,51 $US |
